Karger Publishers –
125 Years of Experience in Medical and Scientific Publishing

Karger Publishers – independent, family-run and Swiss-based.

It is our goal to serve the global scientific community with innovative and outstanding publications in all fields of medical science. This means dedication to maintaining the highest standards of quality, as well as personalized service for authors, editors and readers.

www.karger.com

Please order a free copy of the Karger Festschrift ‘Connecting the World of Biomedical Science’ by sending your address to 125years@karger.com.
Chemotherapy

International Journal of Experimental and Clinical Chemotherapy
Founded 1959 as 'Chemotherapia' by H.P. Kuemmerle and P. Rentchnick
Continued by H. Schönfeld (1968–2001)

Editor-in-Chief
F. Sörgel, Nürnberg-Heroldsberg

Editorial Board
C. Chiesa, Rome
S. Horkovics-Kovats, Kundl
S. Kohno, Nagasaki
C. Landersdorfer, Parkville, Vic.
K. Machka, München
K.G. Naber, Straubing

R. Nau, Göttingen
P. Preziosi, Rome
J.C. Stingl, Bonn
F. Van Bambek, Brussels
M. Wilhelm, Nürnberg
Submission
Only original papers written in English are considered for publication. Manuscripts should be submitted to Chemotherapy online. For specific instructions on how to prepare a manuscript for submission, you are encouraged to view the guidelines at www.karger.com/che, where you will also find a link to the Submission Website. Names, postal and e-mail addresses of four experts in the appropriate area of research should accompany each manuscript. Selected scientist(s) will be invited to act as referee(s). Referees suggested should not be from the same institution as the author and should have expert knowledge of the subject. Should you have any problems with your submission, please contact:

Prof. F. Sörgel
S. Karger AG
Editorial Office ‘Chemotherapy’
PO Box
CH–4009 Basel (Switzerland)
Tel. +41 61 306 1361
Fax +41 61 306 1434
E-Mail che@karger.com

Mailing address for courier deliveries only:
Allschwilerstr. 10
CH–4055 Basel (Switzerland)

Conditions
All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted publication implies the transfer of the copyright from the author to the publisher. Submission of an article for publication but not yet accepted should be noted as ‘unpublished data’ and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples
(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 Mb in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

Author’s Choice
Karger’s Author’s Choice service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

NIH-Funded Research
The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author’s Choice service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH’s Public Access Policy is available at http://publicaccess.nih.gov/FAQ.htm#1

Self-Archiving
Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution’s servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher’s version, and must acknowledge the publisher’s copyright. Authors selecting Karger’s Author’s Choice feature, however, are also permitted to archive the final, published version of their article, which includes copylefting and design improvements as well as citation links.

Page Charges
There is no page charge for papers of 3 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.00. The allotted size of a paper is equal to approx. 9 manuscript pages (including tables, illustrations and references).

Proofs
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations made in proofs, other than the correction of printer’s errors, are charged to the author.

Reprints
Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.
ABSTRACT SUBMISSION
26 January - 28 April 2015

- Present your **groundbreaking data** at the largest European cancer platform
- Take part in **multidisciplinary tumour board** sessions with a clinical orientation
- Discuss the **new developments** in treatment and research that will impact the future of cancer diagnosis and treatment

www.europeancancercongress.org
Contents

See the journal website for contents
We are entering a new and exciting era of microbiological study and application. Recent advances in the now established disciplines of genomics, proteomics and bioinformatics, together with extensive cooperation between academic and industrial concerns have brought about an integration of basic and applied microbiology as never before. The Journal of Molecular Microbiology and Biotechnology (JMMB) aims to reflect this development by publishing original research papers from all areas of microbiology and biotechnology. It also features written symposia on selected topics, timely reviews and minireviews. Theoretical approaches and descriptions of novel, microbiologically relevant software is also considered. Contributions and ideas from large segments of the scientific community are welcome to make JMMB a viable, much-needed and up-and-coming forum for current basic and applied microbiological research.

Journal of Molecular Microbiology and Biotechnology

Editor-in-Chief
M.H. Saier, Jr.,
La Jolla, Calif.

Senior Editors
M.H. Brown,
Adelaide, S.A.
J. Deutscher,
Thiverval-Grignon
G. Gosset,
Cuernavaca
P. Graumann,
Marburg
M. Müller,
Freiburg

D.H. Nies, Halle/Saale
I. Paulsen,
Sydney, N.S.W.
R. Rabus,
Oldenburg
F.X. Soberon,
Cuernavaca
A. Vastermark,
La Jolla, Calif.

Selected contributions
- Microcompartments and Protein Machines in Prokaryotes: Saier Jr., M.H. (La Jolla, Calif.)
- Control of Protein Function through Regulated Protein Degradation: Biotechnological and Biomedical Applications: Nagpal, J.; Tan, J.L.; Truscott, K.N.; Heras, B.; Dougan, D.A. (Melbourne, Vic.)
- Molecular Motors in Bacterial Secretion: Peña, A.; Arechaga, I. (Santander)
- Mechanisms of Cholesterol-Lowering Effects of Lactobacilli and Bifidobacteria Strains as Potential Probiotics with Their bsh Gene Analysis: Öner, Ö.; Aslim, B. (Ankara); Aydaş, S.B. (Gölbaşı/Ankara)
- Evidence for the Involvement of Intracellular Ca²⁺ Ions in the Elicitation Mechanism of Bacillus licheniformis: Reffatti, P.F.; Roy, I.; Odell, M.; Keshavarz, T. (London)
- Arxula adeninivorans Recombinant Urate Oxidase and Its Application in the Production of Food with Low Uric Acid Content: Trautwein-Schult, A.; Jankowska, D. (Gatersleben); Cordes, A.; Hofrichter, P.; Klein, C.; (Wolfenbüttel); Matros, A.; Mock, H.-P. (Gatersleben); Baronian, K. (Christchurch); Bode, R. (Greifswald); Kunze, G. (Gatersleben)
- Membranous Organelles in Bacteria: Saier Jr., M.H. (San Diego, Calif.); Bogdanov, M.V. (Houston, Tex.)
- The Bacterial Magnetosome: A Unique Prokaryotic Organelle: Lower, B.H. (Columbus, Ohio); Bazylinski, D.A. (Las Vegas, Nev.)
- The Coevolutionary Roots of Biochemistry and Cellular Organization Challenge the RNA World Paradigm: Caetano-Anollés, G.; Seufferheld, M.J. (Urbana, Ill.)

More information at www.karger.com/mmb

Impact Factor: 1.487
5-Year Impact Factor: 2.141
151 In vitro Susceptibility of Tigecycline against Multidrug-Resistant Gram-Negative Strains: Etest versus Agar Dilution

185 The Effects of the F-Actin Inhibitor Latrunculin A on the Pathogenic Yeast Cryptococcus neoformans
Kopecká, M. (Brno); Yamaguchi, M.; Kawamoto, S. (Chiba)

162 Obesity and the Use of Antibiotics and Probiotics in Rats
de Sá Del Fiol, F.; Tardelli Ferreira, A.C.M.; Marciano, J.J.; Marques, M.C.; Sant’Ana, L.L. (Sorocaba)

143 Long-Term Everolimus Treatment of Patients with Pancreatic Neuroendocrine Tumors
E.M. Wolin (Lexington, Ky.)

157 Antibacterial Activity of Fosfomycin against Uropathogens
Sun, F.; Chen, S.; Qiu, X.; Sun, Y.; Feng, W.; Chen, J.; Xia, P. (Chongqing)

168 Risk Factors for Cytarabine-induced Cutaneous Toxicity in Patients with Haematological Malignancies
Morio, K. (Osaka/Kyoto); Mizuki, M. (Osaka); Sozu, T. (Kyoto); Uejima, E. (Osaka)

174 French Nationwide Cohort Temporary Utilization Authorization Survey of GranuPAS® in MDR-TB Patients
Kibleur, Y.; Veziris, N. (Paris)

180 Phase I/II Study of Amrubcin and Nedaplatin in Patients with Untreated, Advanced, Non-Small Cell Lung Cancer

191 Full-Dose Gemcitabine Is a More Effective Chemotherapeutic Agent Than 5-Fluorouracil for Concurrent Chemoradiotherapy as First-Line Treatment in Locally Advanced Pancreatic Cancer
Kang, H.; Chang, J.S.; Oh, T.G.; Chung, M.J.; Park, J.Y.; Park, S.W.; Seong, J.; Song, S.Y.; Chung, J.B.; Bang, S. (Seoul)

201 Overall Response to First-Line Tyrosine Kinase Inhibitor and Second-Line Chemotherapy Is Predictive of Survival Outcome in Epidermal Growth Factor Receptor-Mutated Adenocarcinoma

200 ε-Caprolactone Is Not a 50-kDa Molecule when Applied in Micro-Chambered Beads
Draenert, F. (Marburg)